More than 25 million people in the US are known to get affected by Asthma. The present care procedures and devices like bronchodilators and inhaled corticosteroids are not perfect cures to treat the symptoms permanently. The need to find a solution to chronic and uncontrolled asthma, Equillium has initiated the EQUIP Phase 1b clinical trial of Itolizumab (EQ001).
“There continues to be a need for new therapies to treat patients with uncontrolled asthma, many of whom continue to experience symptoms despite the use of current standard of care treatments including bronchodilators and inhaled corticosteroids and, in some cases, existing targeted biologics. Given the heterogeneous and complex biology of this disease, there is a need for novel targeted therapies with unique mechanisms of action that could be effective across the spectrum of asthma phenotypes, regardless of eosinophil levels,” said Prof. Jo Douglass, M.D., head of Immunology and Allergy at Royal Melbourne Hospital and principal investigator of the EQUIP Phase 1b study.
The primary aim of the study and clinical trial is to ascertain the potency of (EQ001) in treating patients with moderate to severe asthma. The biotechnology company will evaluate the safety and tolerability of itolizumab. The trial began early June 2019. The entire study is being taken forward under the guidance of Prof. Douglass with trials been conducted at the best Asthma care centres in New Zealand and Australia.
Equillium has mobilized active and action research in the area of immunobiology to develop products to that could potentially treat autoimmune and inflammatory disorders with high unmet medical need.